Product Description
ARTEMEQ (Artesunate/Mefloquine) is a medication used to treat malaria. It is a fixed dose combination of artesunate & mefloquine. Specifically it is recommended to treat uncomplicated falciparum malaria. It is taken by mouth.
Side effects are similar to the medications being used separately. Use is recommended as it decreases the possibility of either medications being used alone. Dose forms appropriate for children are also available.
Package:
- Tablets (200mg+250mg) 12 tablets/blister*1 /box , 300 boxes/carton
- Tablets (400mg+500mg) 6 tablets/blister*1 /box , 300 boxes/carton
- Tablets (25mg+50mg) For Children 12 tablets/blister*1 /box , 300 boxes/carton
ARTEMEQ is a medication used to treat malaria.It is a fixed dose combination of artesunate and mefloquine. Specifically it is recommended to treat uncomplicated falciparum malaria.It is taken by mouth.
Side effects
Side effects are similar to the medications being used separately.
Use
Use is recommended as it decreases the possibility of either medications being used alone.
Dose forms appropriate for children are also available.
| Weight (kg) | Age | Recommended Dose |
| 5 – < 9 | 6 – <12 months | One ARTEMEQ 25/50mg Fg daily for 3 days |
| 9 – < 18 | 1 – <7 years | Two ARTEMEQ 25/50mg daily for 3 days |
Artesunate is a medication for treating malaria. The intravenous form is preferred over quinine for severe cases. It’s often used in combination therapy, like artesunate plus mefloquine. It isn’t used for malaria prevention. Artesunate can be administered by vein injection, muscle injection, orally, or rectally.
Amodiaquine is a drug for treating malaria, including uncomplicated Plasmodium falciparum malaria. It’s recommended to be given with artesunate to lower the risk of resistance. Due to the risk of rare but serious side effects, it’s not generally advised for malaria prevention. However, the World Health Organization (WHO) recommended its use for seasonal prevention in high-risk children in combination with sulfadoxine and pyrimethamine in 2013.